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Mostcardiacdiseasescausedbyinﬂammationareassociatedwithﬁbrosisintheheart.Fibrosisischaracterizedbytheaccumulation
of ﬁbroblasts and excess deposition of extracellular matrix (ECM), which results in the distorted organ architecture and function.
Recent studies revealed that cardiac ﬁbroblasts are heterogeneous with multiple origins. Endothelial-mesenchymal transition
(EndMT) plays important roles in the formation of cardiac ﬁbroblasts during pathological settings. EndMT is regulated by signal-
ing pathways mediated by cytokines including transforming growth factor (TGF)-β. Better understanding of the mechanisms of
theformationofcardiacﬁbroblastsviaEndMTmayprovideanopportunitytodeveloptherapeuticstrategiestocureheartdiseases.
1.Introduction
Many of heart injuries end up in a common ﬁnal pathway of
pathologic tissue remodeling and ﬁbrosis (deﬁned by depo-
sition of collagens, elastin, tenascin, and other matrix pro-
teins), leading to the development of heart failure. Myocar-
dial ﬁbrosisinduced bycardiacﬁbroblastsplays adualrole in
cardiac remodeling after injury. While ﬁbrosis plays impor-
tant roles in wound healing, it also contributes to ventricular
stiﬀening and heart failure progression. Recent reports
have revealed that cardiac ﬁbroblasts originate through the
mesenchymal transition of endothelial cells (ECs) [1], which
is termed “endothelial-mesenchymal transition (EndMT).”
Here, after updating current views on the sources of cardiac
ﬁbroblasts, we will review epithelial mesenchymal transition
(EMT), in which epithelial cells acquire mesenchymal phe-
notype, since this process has many similarities with EndMT
and lays the groundwork for understanding EndMT. We
will then review the roles of EndMT in physiological and
pathological settings and address its potential mechanisms.
2. Source of Fibroblasts duringCardiacFibrosis
Several lines of evidence suggest that cardiac ﬁbroblasts are a
heterogeneous population and derive from various distinct
tissue niches in physiological and pathological conditions.
During embryonic heart development, cardiac ﬁbroblasts
are diﬀerentiated from epicardium or endocardium of the
heart [2–6]. In a healthy adult heart, cardiac ﬁbroblasts
reside in the interstitial tissue within the myocardium. Some
reportshaveshownthatheart-residentcardiacﬁbroblastsare
the major source of tissue ﬁbrosis associated with ischemic
heart failure and hypertrophy [7, 8]. In addition, ﬁbroblasts
originated from bone marrow-derived cells including CD45-
positive hematopoietic stem cells (HSCs) have also been
shown to signiﬁcantly contribute to remodeling of the
injured heart [9–13]. Finally, emerging evidence suggests
that a subset of cardiac ﬁbroblasts is originated from ECs
in a mouse model of pressure overload [1]. This endothelial
mesenchymaltransitionhascommonfeatureswithepithelial
mesenchymal transition. Taken together, cardiac ﬁbroblasts
are thought to be derived from resident ﬁbroblasts, bone
marrow-derived cells, and ECs.
3. Epithelial-Mesenchymal Transition(EMT)
EMT is a process in which epithelial cells lose their polarity
and cell-to-cell contacts and undergo a dramatic remodeling
of the cytoskeleton (Figure 1(a)) [14, 15]. During EMT,
there is a marked decrease in the expression of epithelial2 International Journal of Inﬂammation
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Figure 1: Schematic representation of mesenchymal transition of epithelial (a) and endothelial (b) cells.
markers including E-cadherin, claudin, zona occludens-1
(ZO-1), and cytokeratin-18, and concurrent increase in the
expression of mesenchymal markers including smooth mus-
cle α-actin (SMA), ﬁbroblast-speciﬁc protein 1 (FSP1; also
known as S100A4), ﬁbronectin, and collagens. Furthermore,
the mesenchymal cells manifest migratory and proliferative
p h e n o t y p e s .E M Th a sb e e ni m p l i c a t e di nm a n yc r i t i c a l
steps during embryonic development including gastrulation
and formation of various tissues or cell clusters (neural
crest, musculoskeletal system, cranial facial structures, and
peripheral nervous system).
Emerging evidence suggests that EMT is also involved
in tissue injury leading to tissue ﬁbrosis [16]. For example,
EMT is associated with progressive ﬁbrosis in kidney disease.
Whileﬁbroblastsarenotparticularlyabundantinthenormal
kidney, there is a marked increase in the number of ﬁbrob-
lastsattheonsetofﬁbrogenesis[17].Furthermore,EMTalso
contributes to the ﬁbrotic responses observed in several lung
pathologies, such as rejecting lung allografts, silica-induced
lung carcinogenesis, and in idiopathic pulmonary ﬁbrosis
[18].
4.SignalingPathwaysMediatedby TGF-β
FamilyMembers
Although EMT has been implicated in many pathological
processes described above, our knowledge of the molecu-
lar events that govern EMT remains relatively undeﬁned.
Transforming growth factor-β (TGF-β) is a multifunctional
cytokine that plays many aspects of cell development, dif-
ferentiation, and homeostasis, and suppresses their uncon-
trolled proliferation and transformation.
TGF-β belongs to the TGF-β superfamily, which includes
33 members in mammals; these include TGF-βs, bone mor-
phogenetic proteins (BMPs), activins and inhibins, Nodal,
myostatin, and M¨ ullerian-inhibiting substance (MIS, also
known as anti-M¨ ullerian hormone) [19]. Members of the
TGF-β family bind to two diﬀerent types of serine/threonine
kinase receptors (Figure 2). Upon ligand binding, the consti-
tutivelyactivetypeIIreceptorkinasephosphorylatesthetype
I receptor which, in turn, activates the downstream signal
transduction cascades, including Smad pathways. TGF-βs,
activin, and Nodal signal through type I receptors are known
as activin receptor-like kinase (ALK)-4, -5, and -7, respec-
tively. The activated type I receptors phosphorylate receptor-
regulated Smad proteins (R-Smads). Smad2 and 3 transduce
signals for TGF-βs and activins, while Smad1, 5, and 8 are
speciﬁc for signaling of BMPs [20]. As an exception, ALK-
1, preferentially expressed in ECs, binds TGF-β and activates
Smad1/5 pathways [21]. Recently, BMP-9 and BMP-10 were
reported to bind to ALK-1 [22, 23]. Once activated, R-Smads
complex with the common mediator Smad4 (co-Smad) and
translocate to the nucleus, where Smad complexes regulate
transcription of target genes through their interaction with
various transcription factors.
In addition, TGF-β has been shown to activate diverse
non-Smad parallel downstream pathways, such as extra-
cellular signal-regulated kinase (ERK), c-Jun NH2-terminal
kinase (JNK), and p38 MAP kinase [24]( Figure 3). Further-
more, TGF-β activates the RhoA during EMT [25]. The Rho
family of small GTPases is comprised of RhoA, Rac1, and
Cdc42 and regulate the formation of stress ﬁbers, lamel-
lipodia, and ﬁlopodia, respectively [26]. Moreover, RhoA
activation is also essential for TGF-β stimulation of SMA
expression in renal epithelial cells undergoing EMT [27].
Taken together, these studies point to the overall importance
of noncanonical TGF-β signaling as well as canonical TGF-
β/Smad signaling to induce EMT in epithelial cells.
5.Other Signaling Pathways and Transcription
Factors Involvedin EMT
Several transcription factors, such as Snail, Slug, δEF1, SIP1,
and Twist, have been implicated in EMT [28]. Snail, a zinc-
ﬁnger containing transcription factor, represses E-cadherinInternational Journal of Inﬂammation 3
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Figure 2: Smad signal transduction pathways mediated by TGF-β and BMP family members.
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Figure 3: Non-Smad signal transduction pathways mediated by TGF-β family members.
expression and induces EMT when overexpressed in epithe-
lial cells [29, 30]. Knockout mice deﬁcient for Snail gene die
at gastrulation as they fail to undergo a complete EMT pro-
cess, forming an abnormal mesodermal layer that maintains
E-cadherin expression [31]. While TGF-β signals have been
shown to induce the expression of Snail, SIP1, and δEF1 dur-
ingEMTofmammaryepithelialcells[32,33],thecausalrela-
tionship between TGF-β-induced Snail expression and EMT
hasnotyetbeenfullyelucidated.Ininﬂammatoryconditions
in which ﬁbrosis is accelerated, the eﬀect of inﬂammatory
cytokines such as TNF-α cannot be disregarded. Stability of
Snail protein was found to be increased by TNF-α in most
cancer cell lines, which results in the elevated migration and
invasion [34]. TNF-α also imparts breast cancer cells with
a stem cell-like phenotype by inducing Slug expression via
NFκB[35],amajortranscriptionfactorthatfunctionsdown-
stream of TNF-α. Furthermore, several lines of evidence sug-
gest that TGF-β and TNF-α synergistically induce the EMT4 International Journal of Inﬂammation
of lung carcinoma cells [36, 37], suggesting that TGF-β and
other inﬂammatory signals collaborate to induce the mes-
enchymal transition of epithelial cells via regulation of EMT-
related transcription factors. It is of our great interest that
EMT-related transcription factors may also be involved in
EndMT. Therefore, we will later discuss recent works on the
involvement of EMT-related transcription factors in EndMT.
6.Endothelial-Mesenchymal
Transition(EndMT)
Blood vessels are lined by ECs and, except for capillaries, sur-
rounded by mural cells (pericytes or smooth muscle cells).
ECsexhibitawiderangeofphenotypicvariabilitydepending
on local physiological requirement throughout the vascular
network [38]. Furthermore, in pathologic conditions, the
endothelium can be aﬀected in a number of ways. One of
the most remarkable ways is an extreme form of endothelial
plasticity known as EndMT. During EndMT, resident ECs
delaminate from a polarized cell layer and invade the
underlying tissue (Figure 1(b)). This so-called mesenchymal
phenotype can be characterised by loss of cell-cell junctions,
acquisition of invasive and migratory properties, loss of EC
markers, such as VE-cadherin and platelet endothelial cell
adhesion molecule-1 (PECAM-1, also known as CD31), and
gainofmesenchymalmarkers,suchasSMAandFSP1[1,39–
43]. Several lines of evidence have suggested that EndMT
is involved not only in pathological [1, 43–45] but also in
physiological conditions, such as the development of heart
[46].
7. EndMT duringHeartDevelopment
During heart development, heart tube consists of two layers,
an inner endocardium and an outer myocardium, which are
s e p a r a t e db ya na c e l l u l a rl a y e ro fe x t r a c e l l u l a rm a t r i x ,s o -
called the cardiac jelly. Endocardial cells acquire endothelial
cell markers, such as VE-cadherin and PECAM1. After the
formation of cardiac cushion, signals from the outﬂow tract
and atrioventricular (AV) myocardium stimulate transfor-
mation of the endocardial cells around the AV cushion
and outﬂow tract into mesenchymal cells through EndMT
to generate the primordia of the valves and membranous
septa [47, 48]. This notion that valvular ﬁbroblasts in the
heart originate from endocardium was clearly conﬁrmed
by lineage analysis. In order to study cell fates in mice,
Zeisberg and colleagues made use of the R26Rosa-lox-STOP-
lox-LacZ; Tie2-Cre (Rosa26-Tie2) double-transgenic reporter
mice [1]. In Rosa26-Tie2 mice, EC-speciﬁc Cre recombinase
removestheﬂoxedSTOPcassette,andtheLacZreportergene
is constitutively expressed under the control of ubiquitous
R26R promoter. Therefore, all endothelial cells and their
derivatives in this transgenic mouse will be irreversibly
labeled with LacZ (β-galactosidase). Through this fate map-
ping studies, Zeisberg and colleagues found that EndMT
occurs only in heart valves in physiological condition.
Slug, a well-known TGF-β target gene, especially, in the
context of EMT, is a direct target of Notch and is required for
initiation of cardiac EndMT [46]. Slug (−/−) embryos had
signiﬁcant fewer mesenchymal cells than wild-type control,
indicating Slug is required for cardiac EndMT. Slug, but
not Snail, is directly upregulated by Notch in ECs and
is required for Notch-mediated repression of VE-cadherin
expression. They also observed that CD31 expression is
downregulated in ECs overexpressing Notch or Slug. These
results suggest that Slug is involved in repressing EC markers
although upregulation of mesenchymal markers depends
on other transcription factors. Slug may be involved in
only repressing EC markers during EndMT. Slug-deﬁcient
embryos increased Snail expression and knockdown of Snail
expression in Slug (−/−) embryos signiﬁcantly reduced AV
canals, indicating that Snail expression can compensate for
Slug deﬁciency and the redundant role of these Snail family
members for cardiac cushion formation during cardiac
EndMT.
8.Roles of TGF-β Family Signals in the EndMT
duringHeartDevelopment
In vitro studies using tissue explants cultures in three-
dimensional collagen gels have revealed the roles of TGF-
β family members in cushion formation. More recently,
analyses of knockout mice deﬁcient in various signaling
components have also shown that in addition to TGF-β
family signals, multiple signaling pathways are involved in
directing EndMT during cushion formation [49, 50].
Both in vitro and in vivo studies have shown that TGF-
β2 plays central roles in endocardial EndMT. Among three
members of TGF-β family (TGF-β1, 2, and 3), only TGF-
β2 is expressed and required for endocardial cushion cell
transformation in the mouse [51] since TGF-β2-deﬁcient
mice have multiple defects in the formation of AV cushion
[52]. However, in the absence of endoglin, TGF-β2w a sn o t
able to induce AV cushion transformation, suggesting that
this coreceptor plays an essential role in EndMT. Addition-
ally, loss of the ALK-5, a type I TGF-β receptor, or the
coreceptor endoglin decreased the number of mesenchymal
cells in AV explant cultures [53]. To our interest, although
endothelial-speciﬁc deletion of the TGF-β type II receptor
(TβRII) prevented EMT in in vitro cultures, there were no
EMTdefectsobservedinthe developing mouse embryo[54],
suggesting a compensatory mechanism by other members of
the TGF-β superfamily.
We previously reported that TGF-β plays important
roles during mesenchymal diﬀerentiation of mouse embry-
onic stem cell-derived endothelial cells (MESECs). TGF-β2
induced the diﬀerentiation of MESECs into mural cells with
decrease in expression of an endothelial marker, claudin-5,
and increase in that of mural markers, SMA, SM22α,a n d
calponin [55]. We also showed that TGF-β-induced Snail
expressionisnecessaryfortheEndMTofMESEC,suggesting
that EndMT and EMT share a common signal-transcription
network to induce the changes in the expression of endothe-
lial/epithelial and mesenchymal markers.
Multiple reports have shown that BMP2 released from
the myocardium acts as an inductive signal initiating theInternational Journal of Inﬂammation 5
onset of EndMT [56, 57]. This myocardial signal leads to
increased TGF-β synthesis in the endocardial cells, and this
autocrine TGF-β induces EndMT [40]. While BMP signals
induce EndMT in explant cultures [56], only limited genetic
evidence has been obtained due to the early lethality of mice
deﬁcient in several BMP components. BMPs signal through
speciﬁc type I receptors including ALK-2, 3, and 6. The
ALK-2deﬁciencyintheendotheliumresultedinthedefective
AV canal formation [58], and endothelial-speciﬁc deletion of
ALK-3 [59] showed that ALK-3 is also required for EndMT
of the heart. Additionally, cardiac muscle lacking ALK-3
expressionisalsodeﬁcientinTGF-β2[60],supportingatwo-
step model for EndMT. Analyzing double-mutant embryos
of the homeobox transcription factors Msx1 and Msx2,
downstream eﬀectors, and upstream regulators of BMP
signaling revealed reduced number of SMA-positive cells
in the AV cushions [61]. Smad4, a common downstream
mediator of both TGF-β and BMP signals, is crucial for heart
development. Smad4-deﬁcient endocardial cells fail to pro-
liferateanddonotundergoEndMT,retainingmorphological
features of ventricular endocardium and decreased Id2 gene
expression. Smad4 and GATA-4 interact in endocardium
to induce Id2 expression cooperatively. In accordance with
these ﬁndings, human GATA-4 mutations by which GATA-4
cannot bind to Smad4 cause atrioventricular septal defects
due to loss of Id2 expression [62]. Taken together, TGF-β
and BMP signals play essential roles in the EndMT-mediated
formation of the valves and septa of the developing heart,
providing a source of mesenchymal cells to form the valves
and septa.
9. Roles of EndMT inCardiacFibrosis
Using the Rosa26-Tie2 reporter mouse described above,
Zeisberg and colleagues performed fate mapping to trace
the origin of the ﬁbroblasts in cardiac ﬁbrosis. Cardiac
ﬁbrosis was induced in these mice by exposing the heart to
pressure overload for 5 days via aortic banding. Analysis of
the ﬁbrotic lesions revealed the presence of cells expressing
both β-galactosidase (LacZ) and FSP1, a ﬁbroblast marker.
Analyzing ﬁbrotic hearts of transgenic mice expressing green
ﬂuorescent protein (GFP) under the control of the FSP1 pro-
moter showed the presence of GFP and PECAM-1 double-
positive cells. These studies demonstrated that endothelial
cells undergo EndMT and contributed to the total pool of
cardiac ﬁbroblasts, as observed during formation of the AV
cushion in developing heart. Interestingly, in the ﬁbrotic
heart, approximately one-third of all ﬁbroblasts were found
to be originated from endothelial cells.
Two other groups have described the roles of EndMT
in cardiac ﬁbrosis. They used coimmunostaining method of
endothelial and mesenchymal markers, instead of the irre-
versible fate mapping method to identify EndMT. Widyan-
toro and colleagues showed that endothelial cell-derived
Endothelin-1(ET-1) promotes cardiac ﬁbrosis via EndMT in
streptozotocin-induced diabetic mouse model [44]. Cardiac
function is decreased and perivascular ﬁbrosis is enhanced in
diabetic mice. Diabetes upregulated the production of ET-1
and TGF-β. Fibrosis markers, S100A4/FSP-1, Vimentin, and
collagen 1α are regulated in CD31-positive cells, and an EC
marker,VE-cadherin,isdownregulatedindiabeticmice.EC-
speciﬁc deletion of ET-1 ameliorates these EndMT-related
geneexpressionchanges.Theyalsoaddressedthemechanism
by which ET-1 induces EndMT in cultured EC. They showed
that ET-1 induces the TGF-β expression and claimed that
TGF-β-Akt-Snail-axis is involved in this EndMT.
Ghosh and colleagues found deletion of plasmino-
gen activator inhibitor-1 (PAI-1) results in constitutive
active TGF-β signaling in aged mice [45]. Expression of
Collagen1A1, TGF-β2, MMP-2, FGF-2, and its receptor,
FGFR2, is also upregulated in aged mice. Importantly, in
resemblance to EndMT, FGF signals play important roles
in producing activated ﬁbroblasts during EMT [63, 64].
The number of Mac-3-positive cells increased in the PAI-
1 null heart, indicating that inﬂammation occurred and
inﬁltrating macrophage may contribute to the pathogenesis
and progression of cardiac ﬁbrosis in PAI-1-deﬁcient mice.
Phosphorylation of Smad2 and ERK1/2 is also enhanced
in the PAI-1 null heart, indicating upregulation of TGF-
β signals. In their in vitro analysis, expression of CD31
decreases in concomitant with upregulation of FSP-1 and
SMA in the PAI-1 null EC.
All of the works listed above suggested that TGF-β signal
plays a critical role in cardiac ﬁbrosis. It is of great interest
whether EndMT-mediated cardiac ﬁbrosis is regulated by
other components of TGF-β signals and TGF-β-induced
EMT-related transcription factors.
10.RolesofTGF-β FamilySignalsintheCardiac
FibrosisThat Does Not InvolveEndMT
TGF-β is one of the critical regulators of cardiac ﬁbrosis.
Therefore, some groups have recently reported the roles of
TGF-β family signals in cardiac ﬁbrosis in which EndMT is
not involved.
GDF15 (also known as MIC-1), a secreted member
of the TGF-β superfamily, was identiﬁed as an antihy-
pertrophic regulatory factor in the heart [65]. GDF15 is
not expressed in the normal adult heart but is induced
in response to conditions that promote hypertrophy and
dilated cardiomyopathy. GDF15 transgenic mice were nor-
mal but were partially resistant to pressure overload-
induced hypertrophy. Conversely, GDF15 knockout mice
showed enhanced cardiac hypertrophic growth following
pressure overload stimulation. GDF15 knockout mice also
demonstratedapronouncedlossinventricularperformance.
GDF15 stimulation promoted phosphorylation of Smad2/3
in an in vitro analysis. Overexpression of Smad2 attenuated
cardiomyocyte hypertrophy similar to GDF15 treatment,
whereas overexpression of the inhibitory Smad proteins,
Smad6/7, reversed the antihypertrophic eﬀects of GDF15.
Therefore, GDF15 is an autocrine/endocrine factor that
antagonizesthehypertrophicresponseandlossofventricular
performance and may be a candidate molecule for treating
cardiac hypertrophy clinically.
TGF-β-ALK-5 signals are involved in GATA-6-mediated
angiogenic function and survival in ECs [66]. Knockdown6 International Journal of Inﬂammation
of GATA-6 decreased proliferation, migration, and tube
formation of ECs. This eﬀect was partially rescued by
TGF-β-neutralizing antibody or ALK-5 inhibitor. GATA-6
suppresses TGF-β expression in EC, which results in down-
regulation of phosphorylation of Smad2 without aﬀecting
phosphorylation of Smad1, suggesting that GATA-6 sup-
presses only TGF-β-ALK-5 signals but not TGF-β-ALK-1
signals for exerting angiogenic function.
Sarcomere protein mutation (a-MHC R719W) causes
hypertrophic cardiomyopathy, a disorder characterized by
myocyte enlargement, ﬁbrosis, and impaired ventricular
relaxation. This mutation activates proliferative and proﬁ-
brotic signals in nonmyocyte cells to produce TGF-β,a n d
its responsive genes such as periostin. In treatment of
TGF-β-neutralizing antibody or Losartan, an AT1 blocker
abrogates nonmyocyte proliferation and ﬁbrosis probably by
blocking both TGF-β signals but through unknown precise
mechanism [67]. Once again, TGF-β is one of the main
causes of ﬁbrosis here and can also be an eﬃc i e n tt a r g e tf o r
ameliorating ﬁbrotic microenvironments in the heart.
11. FuturePerspectiveandConcludingRemarks
The recent ﬁndings that EndMT is involved in diﬀerent dis-
easessuggestthatmodulating EndMT mayserveapromising
new therapeutic strategy for heart diseases and cancer. The
endothelium is a promising target for drug delivery because
it lies in direct contact with the bloodstream. Possible treat-
ment strategies may target the TGF-β signaling pathways.
We found that inhibition of endogenously activated TGF-
β signals in ECs [68] by a small molecule that inhibits
kinases of receptors for TGF-β led to a decrease in EndMT,
suggesting that inhibition of TGF-β signals may suppress
EndMT. Interestingly, Zeisberg and colleagues demonstrated
that systemic administration of recombinant human BMP-
7 (rhBMP-7) signiﬁcantly reduced EndMT during cardiac
ﬁbrosis [1]. Additional studies are needed to identify the
precise molecular mechanisms by which BMP-7 inhibits the
EndMT.
Furthermore, accumulating evidence suggests that
EndMT not only induces the formation of ﬁbroblasts in
cardiac ﬁbrosis but also in other ﬁbrotic disorders in-
cluding intestinal ﬁbrosis [69] and kidney ﬁbrosis [70].
In conclusion, EndMT is expected to be a target for the
developmentofnewtherapiesformultipleﬁbroticdisorders.
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